Symposium funding request for "Multivalent Drug Design"

描述（由申请人提供）：题为“多价药物设计”的研讨会将于2011年3月27日至31日在加利福尼亚州阿纳海姆的阿纳海姆会议中心举行的美国化学学会（ACS）全国会议上举行。本次研讨会将是美国化学学会有机化学分部提供的计划的一部分，旨在讨论与生物识别事件有关的多价相互作用的研究进展。来自学术界、政府和工业界的科学家将分享在传统小分子治疗发展中存在问题的领域开发多价抑制剂的最新成果。这项提议要求$11 050作为专题讨论会的部分支助。NIGMS的财政支持将允许我们为四名研究生和/或博士后提供参加会议的旅费。此外，美国国立卫生研究院的支持将用于抵消六名研讨会演讲者的旅行和酒店费用。研讨会将集中讨论多价治疗剂发展的基本进展。多价疾病包括艾滋病、肝炎、流感、耐甲氧西林金黄色葡萄球菌、结核病、链球菌、葡萄球菌、阿尔茨海默病、亨廷顿氏病、肌萎缩侧索硬化症、糖尿病和癌症；这类疾病的多价疗法应解决许多传统单价材料无法解决的问题。以多价方式进行的科学研究使许多技术进步能够对公共卫生产生直接影响。本次研讨会的预期成果是为早期职业科学家提供一个独特的机会，让他们了解多价方法在治疗发展中的作用，并在许多主题领域发起和建立全球合作，包括那些对生物医学进步至关重要的领域。专题讨论会将大大增加跨学科相互作用的机会。

DESCRIPTION (provided by applicant): The symposium entitled "Multivalent Drug Design" will occur at the national meeting of the American Chemical Society (ACS) at the Anaheim Convention Center in Anaheim, California, on March 27-31, 2011. This symposium, which will be part of the program offered by the ACS Division of Organic Chemistry, has been organized to discuss advances in research about multivalent interactions as they pertain to biological recognition events. Scientists from academia, government, and industry will share the latest results on the development of multivalent inhibitors in areas that have been problematic for traditional small molecule therapeutics development. This proposal requests $11,050 for partial support of the symposium. Financial support from NIGMS will allow us to provide travel grants for four graduate students and/or postdoctoral students to attend the conference. In addition, support from NIH will be used to offset travel and hotel expenses for six symposium speakers. Discussions at the symposium will focus on fundamental advances in the development of multivalent therapeutic agents. Diseases with multivalent aspects include AIDS, hepatitis, influenza, methicillin-resistant Staphylococcus aureus, tuberculosis, Streptococcus, Staphylococcus, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, diabetes, and cancer; multivalent therapeutics for such diseases should address many problems that traditional monovalent materials cannot. Scientific research conducted in multivalency enables many of the technology advances that have direct impact on public health. The expected outcomes of this symposium are to provide a unique opportunity for early-career scientists to gain an appreciation for the role that multivalent approaches can play in therapeutic development and to initiate and build on collaborations globally in many topical areas, including those that are essential to advances in biomedicine. Opportunities for interdisciplinary interactions will be significantly enhanced by the symposium. PUBLIC HEALTH RELEVANCE: The ability to modulate multivalent interactions would provide control over countless biological processes. Successful discovery and development of new and exciting agents would help address major medical needs. The increasing expense and risk in small molecule drug discovery has highlighted the need for new approaches and technologies that can improve the success rate of drug candidates and reduce their attrition in development. This symposium will focus on new approaches and enabling technologies that will contribute to the identification of such agents.